Hunger and the gut hormone GLP-1
How does Tirzepatide act like the gut hormone GLP-1?
Hunger can return soon after you've eaten a good meal. The studies tested changes in appetite, sugar and weight. Your health needs more than a brochure's biggest claim.
What does the weekly shot do?
A full plate doesn't always keep hunger away until supper. Tirzepatide is a weekly shot that helps lower sugar and weight. Insulin, a hormone made by your body, brings blood sugar down. High sugar prompts the medicine to help release more insulin.
Approval covered type 2 diabetes in May 2022 and obesity in November 2023. Later approval covered obesity with sleep apnea, when breathing repeatedly stops at night. The shot goes beneath the skin rather than into a vein. Those approvals still leave health risks for your doctor to weigh.
The gut releases hormones after meals, including GIP and GLP-1. Tirzepatide copies both, while earlier drugs mainly copy the second hormone. Studies tested whether this added action helped people more. A drug's action doesn't set the amount of weight you'll lose.
The weight trials lasted months; they didn't follow people for life. SURMOUNT-1 enrolled 2,539 adults and found 20.9% average loss over 72 weeks at the highest amount. SURMOUNT-5 followed 751 adults for the same time. Average loss was 20.2% with tirzepatide and 13.7% with another weight medicine [4][5].
A smaller study checked insulin release and how well insulin lowered sugar. Tirzepatide improved both together more than the comparison medicine [8][9]. That's useful support for the larger trial findings, with the smaller study's limits. Reported changes and risks include the less welcome results.
What has Tirzepatide shown beyond the largest weight claim?
Tirzepatide's early research name was LY3298176; both names refer to the same medicine. The drug has a 39-amino-acid chain made from the small parts used in proteins. GIP and GLP-1 come from the gut and urge insulin release after eating. Raised blood sugar prompts tirzepatide to copy both hormone actions.
The first detailed work grew cells in lab dishes, without treating patients. The tests found greater strength through GIP than through GLP-1. With GLP-1, the medicine kept the insulin-making cells ready to respond longer [2]. Researchers think this longer cell response may explain some benefits found in patients.
The medicine has a fatty part that attaches to a blood protein. That protein slows how quickly the body clears the medicine. About half takes five days to leave the blood [1]. This longer stay supported the weekly shots tested in people.
SURPASS involved adults with type 2 diabetes, rather than everyone with raised sugar. Phase 3 means the large trials held before approval to weigh safety and benefit. Over 40 weeks, researchers tested weekly amounts of 5, 10, and 15 milligrams. Each amount outperformed semaglutide 1 milligram, another diabetes medicine, on the three-month sugar blood test [3].
People on tirzepatide also lost more weight. The blood test reflects sugar over several months, unlike your morning reading. A lower test result means less sugar remained in the blood over that time. The study found a larger fall at the higher amounts.
SURMOUNT tested adults with excess weight who didn't have diabetes. At 72 weeks, average loss was 20.9% with 15 milligrams and 3.1% with placebo, a shot containing no active drug [4]. SURMOUNT-5 followed 751 adults for 72 weeks. Tirzepatide brought 20.2% average loss, compared with 13.7% on the other weight medicine [5].
Heise's 2022 insulin study was small, with only 117 people. The tests checked insulin release and how effectively insulin lowered sugar. Tirzepatide improved both together more than placebo or semaglutide [8]. The small study supports a benefit, without fixing its exact size.
Researchers calculated ranges because chance differences between groups can affect the size of a result. In repeated studies, the placebo comparison's method would cover the true difference 95% of the time. The semaglutide comparison used that same 95% method. Those numbers describe the method, not how many patients benefited.
Later trials tested night breathing stops, fatty liver disease and a form of heart failure. The patients' hearts squeezed normally, yet didn't fill properly between beats. That can leave too little blood moving through the body. The liver patients had swelling and scarring; each finding applies to the illness studied.
Which Tirzepatide results have enough detail to judge?
A large loss on a brochure can hide who was studied. The trials below involved different patients over different lengths of time. Each result needs those details before you can judge its value. Your own weight change won't necessarily match a trial average.
Adults with type 2 diabetes: SURPASS-2 followed 1879 people for 40 weeks. At 15 milligrams weekly, the three-month sugar blood test showed a greater drop than semaglutide 1 milligram [3]. Doctors use semaglutide to treat diabetes and help with weight loss. Tirzepatide also brought greater weight loss at all three tested amounts.
Adults with obesity, without diabetes: SURMOUNT-1 enrolled 2539 adults for 72 weeks. Average losses were 15.0%, 19.5%, and 20.9% with 5, 10, and 15 milligrams; placebo brought 3.1%. Placebo means a shot containing no active medicine. At 15 milligrams, 96% lost at least 5% of their weight; 56% lost at least 20% [4].
Comparing weight medicines: SURMOUNT-5 followed 751 adults for 72 weeks. Tirzepatide users lost 20.2% on average, compared with 13.7% on the other medicine. More tirzepatide users reached losses of 10%, 15%, 20%, and 25% [5]. The tirzepatide group also had greater reductions in waist size.
Checking insulin: Heise's 2022 trial involved just 117 people over 28 weeks. Tirzepatide improved insulin release and insulin's ability to lower sugar more than placebo or semaglutide [8]. Semaglutide copies GLP-1, a hormone from the gut involved in releasing insulin. The findings suggest that copying another gut hormone adds benefit.
Tirzepatide reviews of early changes: Researchers went back over the SURPASS results. A sugar fall of at least 20% by week 4 often preceded better later results. So did a weight fall of at least 5% by week 8. People with slower early changes still gained worthwhile benefits [11].
The research page gives more detail about the insulin and weight studies. Separate trials tested patients with sleep illness, as well as specific heart and liver problems. Those illnesses need their own evidence rather than a borrowed weight claim. Your doctor can judge the findings against the health problems you have.
Why does the Tirzepatide peptide remain in blood for days?
Peptide means protein parts joined into a chain shorter than a protein. Tirzepatide has a 39-amino-acid chain; amino acids make up that chain. Researchers started with the gut hormone GIP and changed its structure. The added fatty part holds onto a protein circulating in blood [1].
The blood protein makes removal of the medicine take longer. After five days, roughly half is still present, supporting weekly trial shots. The drug doesn't disappear as soon as the shot is over. Your response still depends on more than the time spent in blood.
Cell tests found stronger GIP action than GLP-1 action. GLP-1, another hormone from the gut, encourages cells to release insulin. With GLP-1, tirzepatide kept those cells able to respond for longer [2]. Normally, the cell pulls its receptor, the part that responds to the hormone, inside.
In cells grown in lab dishes, tirzepatide left more receptors on the cell surface. Researchers think the cells may therefore release insulin for longer. That's a possible explanation, rather than proof of your likely benefit. The insulin studies tested whether people also released and used insulin better.
Where was Tirzepatide injection given, and why did amounts rise?
Phase 3 means large studies used to judge safety and benefit before approval. Each week, participants received a shot that put the medicine beneath the skin. Researchers used the belly, an upper arm or the thigh for the shot. Those study details don't replace the plan from your prescribing doctor.
The approved plan began with 2.5 milligrams weekly for the opening four weeks. Later increases added 2.5 milligrams after each four-week wait. The highest ongoing amount was 15 milligrams each week. The phase 3 trials tested ongoing amounts of 5 milligrams, 10 milligrams, and 15 milligrams.
Stomach trouble was common, particularly while the trial amounts were rising. People reported constipation and loose stools, as well as nausea and vomiting. The slow increases aimed to ease these problems, which often faded with time [6][13][14]. A gradual rise didn't prevent everyone from feeling ill or stopping treatment.